Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivastigmine Twice-Weekly Patch vs Exelon Patch
NCT05883124Phase 1Completed
- Sponsor
- SocraTec R&D
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) (2 arms), sponsored by SocraTec R&D. Primary endpoints: AUC96-264, Cmax,96-264 and 2 more. Started Apr 2023; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT05883124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883124.